

s 22

From: s 47F
Sent: Monday, 23 December 2019 9:26 AM
To: pricedisclosure
Cc: s 47F
Subject: RE: Notification of Price Disclosure price reductions (2020 April Cycle - with reduction day of 1 April 2020) [SEC=OFFICIAL, ACCESS=Commercial]

Hi,

Please confirm receipt of below s 47G

s 47F

From: s 47F
Sent: Thursday, 19 December 2019 7:41 AM
To: pricedisclosure
Cc: s 47F
Subject: RE: Notification of Price Disclosure price reductions (2020 April Cycle - with reduction day of 1 April 2020) [SEC=OFFICIAL, ACCESS=Commercial]
Importance: High

s 47G

s 47F

From: pricedisclosure s 22
Sent: Wednesday, 18 December 2019 4:14 PM
To: pricedisclosure s 22

Subject: Notification of Price Disclosure price reductions (2020 April Cycle - with reduction day of 1 April 2020)
[SEC=OFFICIAL, ACCESS=Commercial]

Dear Authorised Representative,

[This email is relevant to Authorised Representatives of Responsible Persons with brands of pharmaceutical items subject to price disclosure. Please distribute to any other person in your company with responsibilities related to price disclosure.]

Notice of Price Disclosure Outcomes

Price disclosure price reduction outcomes for the 2020 April Cycle, with a reduction day on 1 April 2020, are now available.

A list of the drug, manner of administration and form of medicines taking a price reduction on 1 April 2020, with relevant ex-manufacturer level weighted average disclosed prices, percentage differences and calculation basis has been published today on the [Price Disclosure](#) web page, under the heading 'Outcomes from Price Disclosure'.

The [legislative instrument](#) determines the ex-manufacturer level weighted average disclosed prices for specific brands. Price reductions will apply to brands of pharmaceutical items with a weighted average disclosed price listed in Schedule 1 of the instrument. Brands of pharmaceutical items with a weighted average disclosed price listed in Schedule 2 of the instrument will not take a price reduction.

Flow-on reductions, including for brands of F2 combination items may be different to the direct reduction determined. Calculations are currently being completed. Outcomes will be communicated to responsible persons with brands of affected drugs in late January 2020.

Any brands that listed after 30 September 2019 for a pharmaceutical item that has a determination in Schedule 1 of the legal determination will also take the reduction on 1 April 2020 by force of section 99ADHA of the *National Health Act 1953*.

Any dispute regarding the published outcomes of this cycle should be sent to the Department by COB Thursday 2 January 2020.

PBS News

[Subscribe to PBS News](#) to receive notification about significant updates to the [PBS Website](#) including notification of price disclosure reduction outcomes and other pricing matters.

Kind regards,

Price Disclosure Team

PBS Price Changes Section

Technology Assessment and Access Division | Health Financing Group
Pricing & PBS Policy Branch
Australian Government Department of Health
s 22

PO Box 9848, Canberra ACT 2601, Australia

The Department of Health acknowledges the traditional owners of country throughout Australia, and their continuing connection to land, sea and community. We pay our respects to them and their cultures, and to elders both past and present.

"Important: This transmission is intended only for the use of the addressee and may contain confidential or legally privileged information. If you are not the intended recipient, you are notified that any use or dissemination of this communication is strictly prohibited. If you receive this transmission in error please notify the author immediately and delete all copies of this transmission."

THIS DOCUMENT HAS BEEN RELEASED
UNDER THE FREEDOM OF INFORMATION ACT 1982 (CTH)
BY THE DEPARTMENT OF HEALTH